Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Fructo-oligosaccharides (FOS) are prebiotic fibers that have been investigated for their potential benefits in inflammatory bowel disorders (IBD), including Crohn’s disease and ulcerative colitis. The rationale for their use is based on their ability to promote beneficial gut microbiota, particularly bifidobacteria, which may modulate immune responses and reduce intestinal inflammation. Several small-scale clinical trials and animal studies have examined FOS supplementation in IBD patients. Some studies report modest improvements in gut microbiota composition and reductions in inflammation markers; however, results are inconsistent, and not all trials have demonstrated clinical benefit. Systematic reviews and meta-analyses generally conclude that while FOS can increase beneficial bacterial populations, robust evidence for meaningful improvements in IBD symptoms or disease progression is lacking. In some cases, FOS supplementation has been associated with increased gastrointestinal symptoms such as bloating or discomfort. Major gastroenterology guidelines do not currently recommend FOS as a standard therapy for IBD. Overall, while there is a scientific rationale and preliminary evidence for FOS as a supportive therapy in IBD, the quality and consistency of clinical evidence is limited, and further well-designed studies are required to clarify its role.

More about Fructo-Oligosaccharides
More about Inflammatory Bowel Disorders

Other ingredients used for Inflammatory Bowel Disorders

Other health conditions supported by Fructo-Oligosaccharides

Products containing Fructo-Oligosaccharides